{"id":"sirolimus-tab","safety":{"commonSideEffects":[{"rate":"30–50%","effect":"Hyperlipidemia"},{"rate":"15–30%","effect":"Thrombocytopenia"},{"rate":"20–30%","effect":"Anemia"},{"rate":"15–25%","effect":"Leukopenia"},{"rate":"10–20%","effect":"Hypertension"},{"rate":"10–20%","effect":"Diarrhea"},{"rate":"10–15%","effect":"Rash"},{"rate":"10–15%","effect":"Mouth ulcers"},{"rate":"10–20%","effect":"Increased creatinine"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sirolimus binds to FKBP12 and forms a complex that inhibits mTOR kinase activity, thereby suppressing T-cell proliferation and reducing immune activation. This mechanism makes it useful as an immunosuppressant to prevent organ rejection and as an antiproliferative agent in certain cancers and vascular diseases.","oneSentence":"Sirolimus inhibits mTOR (mammalian target of rapamycin), a key signaling protein that controls cell growth and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:45.710Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of organ rejection in patients receiving renal transplants"},{"name":"Lymphangioleiomyomatosis (LAM)"},{"name":"Tuberous sclerosis complex (TSC)-associated tumors"}]},"trialDetails":[{"nctId":"NCT06876142","phase":"PHASE1, PHASE2","title":"Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM)","enrollment":54},{"nctId":"NCT06943755","phase":"PHASE2, PHASE3","title":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Exelixis","startDate":"2025-07-21","conditions":"Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)","enrollment":440},{"nctId":"NCT06428396","phase":"PHASE2","title":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-27","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT04141020","phase":"PHASE2","title":"Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms","status":"RECRUITING","sponsor":"University of Miami","startDate":"2021-10-27","conditions":"Cerebral Aneurysm","enrollment":80},{"nctId":"NCT05153668","phase":"EARLY_PHASE1","title":"Everolimus Trial in Laryngotracheal Stenosis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-09-30","conditions":"Idiopathic Subglottic Tracheal Stenosis","enrollment":8},{"nctId":"NCT07435584","phase":"PHASE1, PHASE2","title":"Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"Colorectal Cancer","enrollment":38},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT04469530","phase":"PHASE2","title":"Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-09-16","conditions":"Solid Tumor","enrollment":55},{"nctId":"NCT05193565","phase":"PHASE4","title":"Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-11-19","conditions":"Kidney Transplantation","enrollment":206},{"nctId":"NCT06105632","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-09","conditions":"Advanced or Metastatic Breast Cancer","enrollment":333},{"nctId":"NCT05949658","phase":"PHASE1","title":"Rapalog Pharmacology (RAP PAC) Study","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2024-05-15","conditions":"Aging","enrollment":72},{"nctId":"NCT05476939","phase":"PHASE3","title":"Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2022-09-29","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered","enrollment":433},{"nctId":"NCT02962414","phase":"PHASE3","title":"Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-08","conditions":"Tuberous Sclerosis Complex","enrollment":206},{"nctId":"NCT05252585","phase":"PHASE4","title":"A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-01","conditions":"Renal Angiomyolipoma","enrollment":4},{"nctId":"NCT05237687","phase":"PHASE2","title":"The Role of Sirolimus in Preventing Functional Decline in Older Adults","status":"RECRUITING","sponsor":"Irina Timofte","startDate":"2026-02","conditions":"Aging","enrollment":10},{"nctId":"NCT06727305","phase":"PHASE1, PHASE2","title":"MTOR Inhibitors in Older Adults","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02","conditions":"Aging","enrollment":60},{"nctId":"NCT07024173","phase":"PHASE3","title":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2025-07-23","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":240},{"nctId":"NCT07354620","phase":"EARLY_PHASE1","title":"A Pilot Study on Reverse Aging (The REVERSE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Christ Hospital","startDate":"2025-02-15","conditions":"Aging","enrollment":52},{"nctId":"NCT07350057","phase":"PHASE1","title":"A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graft-versus-Host Disease After Haploidentical Stem Cell Transplantation in Children","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-25","conditions":"GVHD (Acute or Chronic)","enrollment":9},{"nctId":"NCT05933395","phase":"PHASE2","title":"Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2024-09-23","conditions":"Advanced Breast Cancer","enrollment":135},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT07002177","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","status":"RECRUITING","sponsor":"Forward Pharmaceuticals Co., Ltd.","startDate":"2025-06-01","conditions":"Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II","enrollment":196},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT07302932","phase":"NA","title":"Metformin and Molecular Aging in Prediabetes","status":"COMPLETED","sponsor":"Diabetes Foundation, India","startDate":"2023-02-01","conditions":"Metformin, Prediabetes","enrollment":112},{"nctId":"NCT07062965","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-05","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT04948203","phase":"PHASE2, PHASE3","title":"Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2021-07-09","conditions":"Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID","enrollment":60},{"nctId":"NCT03284957","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-20","conditions":"Breast Cancer","enrollment":136},{"nctId":"NCT01797523","phase":"PHASE2","title":"A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-10-07","conditions":"Endometrial Cancer","enrollment":62},{"nctId":"NCT03334617","phase":"PHASE2","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":528},{"nctId":"NCT06261060","phase":"PHASE2","title":"Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-06-20","conditions":"Familial Platelet Disorder, Hematopoietic","enrollment":6},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT07218575","phase":"PHASE2, PHASE3","title":"Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations","status":"NOT_YET_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-04","conditions":"Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease","enrollment":60},{"nctId":"NCT05501769","phase":"PHASE1","title":"ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer","status":"COMPLETED","sponsor":"Arvinas Estrogen Receptor, Inc.","startDate":"2022-09-08","conditions":"Breast Cancer","enrollment":32},{"nctId":"NCT04936854","phase":"PHASE2","title":"Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2023-01-01","conditions":"Thyroid-Associated Ophthalmopathy","enrollment":60},{"nctId":"NCT06680921","phase":"PHASE3","title":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2024-11-14","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":460},{"nctId":"NCT07173556","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09","conditions":"Advanced Breast Cancer","enrollment":96},{"nctId":"NCT01734512","phase":"PHASE2","title":"PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-12-13","conditions":"Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas","enrollment":65},{"nctId":"NCT02123823","phase":"PHASE1","title":"BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-05-15","conditions":"Neoplasms","enrollment":164},{"nctId":"NCT06022068","phase":"PHASE1, PHASE2","title":"Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2023-09-01","conditions":"Alzheimer Disease","enrollment":14},{"nctId":"NCT07033858","phase":"NA","title":"Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation","status":"RECRUITING","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2025-03-01","conditions":"Kidney Transplant; Complications","enrollment":50},{"nctId":"NCT07015684","phase":"PHASE1","title":"131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-04-28","conditions":"Sickling Disorder Due to Hemoglobin S","enrollment":24},{"nctId":"NCT01805271","phase":"PHASE3","title":"Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-03","conditions":"Primary Non-metastatic Breast Cancer, Who Remain Disease-free","enrollment":1278},{"nctId":"NCT00942734","phase":"PHASE2","title":"Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-07","conditions":"Head And Neck Cancer","enrollment":49},{"nctId":"NCT04195750","phase":"PHASE3","title":"A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-27","conditions":"Carcinoma, Renal Cell","enrollment":755},{"nctId":"NCT06942156","phase":"PHASE4","title":"Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-08-14","conditions":"Heart Transplant","enrollment":140},{"nctId":"NCT06941142","phase":"PHASE1","title":"A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-04-30","conditions":"Advanced Breast Cancer","enrollment":382},{"nctId":"NCT05414292","phase":"NA","title":"Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)","status":"RECRUITING","sponsor":"University of Nottingham","startDate":"2021-08-06","conditions":"Muscle Atrophy, Age-Related Sarcopenia","enrollment":16},{"nctId":"NCT03173560","phase":"PHASE2","title":"Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-08-17","conditions":"Renal Cell Carcinoma","enrollment":343},{"nctId":"NCT00866684","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2007-01-01","conditions":"Skin Cancer","enrollment":44},{"nctId":"NCT05269849","phase":"PHASE2","title":"Sirolimus for Nosebleeds in HHT","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2022-03-16","conditions":"Hereditary Hemorrhagic Telangiectasia, Nosebleeds, Epistaxis","enrollment":10},{"nctId":"NCT03659136","phase":"PHASE2","title":"The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-11-28","conditions":"Breast Neoplasms","enrollment":103},{"nctId":"NCT02991807","phase":"PHASE1, PHASE2","title":"RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2017-06-12","conditions":"PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome","enrollment":46},{"nctId":"NCT03150914","phase":"PHASE3","title":"Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2018-01-01","conditions":"LAM, Lymphangioleiomyomatosis","enrollment":60},{"nctId":"NCT06091332","phase":"PHASE2","title":"Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-01-05","conditions":"Cavernous Malformations, Intracerebral Hemorrhage, Brainstem Stroke","enrollment":75},{"nctId":"NCT02216786","phase":"PHASE2","title":"A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-01-16","conditions":"Estrogen Receptor Positive Breast Cancer","enrollment":333},{"nctId":"NCT03095703","phase":"PHASE2","title":"Sirolimus and Familial Adenomatous Polyposis (FAP)","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2017-10-03","conditions":"Adenomatous Polyposis Coli","enrollment":4},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT05663944","phase":"PHASE2","title":"REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. the RESUS Proof of Concept Study","status":"COMPLETED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2022-07-25","conditions":"Advanced Chronic Liver Disease","enrollment":41},{"nctId":"NCT03359538","phase":"PHASE2","title":"Rapamycin Treatment for ALS","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2017-09-19","conditions":"Amyotrophic Lateral Sclerosis","enrollment":63},{"nctId":"NCT03154281","phase":"PHASE1","title":"Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast","status":"COMPLETED","sponsor":"Avera McKennan Hospital & University Health Center","startDate":"2017-07-26","conditions":"Breast Cancer, Ovarian Cancer","enrollment":14},{"nctId":"NCT04393454","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2020-11-16","conditions":"Metastatic dMMR Solid Cancer, Solid Tumor, Cancer","enrollment":6},{"nctId":"NCT05233722","phase":"NA","title":"mTOR as Mediator of Insulin Sensitivity Study","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2022-02-10","conditions":"Insulin Sensitivity","enrollment":10},{"nctId":"NCT01428973","phase":"PHASE2","title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Liege","startDate":"2011-09","conditions":"Graft-Versus-Host Disease, Hematological Malignancies","enrollment":200},{"nctId":"NCT05920512","phase":"PHASE1, PHASE2","title":"Combination Regimen With Sodium Valproate for Severe Hemophilia: a Single-arm, Phase 1, Pilot Trial.","status":"UNKNOWN","sponsor":"Xue-chun Lu","startDate":"2022-04-01","conditions":"Hemophilia","enrollment":10},{"nctId":"NCT02730923","phase":"PHASE1, PHASE2","title":"Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)","status":"UNKNOWN","sponsor":"Centre Leon Berard","startDate":"2016-04","conditions":"Endometrial Carcinoma, Metastatic Carcinoma, Hormone Receptor Positive Tumor","enrollment":72},{"nctId":"NCT03312738","phase":"PHASE2","title":"A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-15","conditions":"Advanced Breast Cancer","enrollment":159},{"nctId":"NCT03877809","phase":"PHASE2","title":"Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients","status":"COMPLETED","sponsor":"Rare Partners srl Impresa Sociale","startDate":"2019-06-27","conditions":"Beta-Thalassemia","enrollment":26},{"nctId":"NCT06160739","phase":"","title":"Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-11-20","conditions":"Microcystic Lymphatic Malformation, Combined Vascular Malformation, Vascular Malformations","enrollment":10},{"nctId":"NCT02258451","phase":"PHASE2","title":"Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-04","conditions":"Breast Neoplasms","enrollment":283},{"nctId":"NCT02599324","phase":"PHASE1, PHASE2","title":"Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2015-12-01","conditions":"Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma","enrollment":263},{"nctId":"NCT00414648","phase":"PHASE3","title":"Efficacy and Safety of Sirolimus in LAM","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2006-12","conditions":"Lymphangioleiomyomatosis","enrollment":89},{"nctId":"NCT03386539","phase":"PHASE3","title":"Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score","status":"UNKNOWN","sponsor":"Boston Children's Hospital","startDate":"2018-01-29","conditions":"Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases","enrollment":211},{"nctId":"NCT00934895","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2009-07-15","conditions":"Breast Cancer","enrollment":27},{"nctId":"NCT03245151","phase":"PHASE1, PHASE2","title":"Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-11-16","conditions":"Recurrent and Refractory Solid Tumors","enrollment":64},{"nctId":"NCT04720664","phase":"PHASE2","title":"Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2021-09-22","conditions":"Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma","enrollment":11},{"nctId":"NCT04993872","phase":"PHASE4","title":"Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF","status":"UNKNOWN","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2022-09-29","conditions":"HIV-infected Patient Kidney Transplant Recipient","enrollment":5},{"nctId":"NCT03217669","phase":"PHASE1","title":"Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy","status":"UNKNOWN","sponsor":"Chao Huang","startDate":"2018-02-22","conditions":"Advanced Solid Tumor, Non-small Cell Lung Cancer (NSCLC)","enrollment":15},{"nctId":"NCT01698918","phase":"PHASE2","title":"Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-07","conditions":"Hormone Receptor Positive Breast Cancer","enrollment":202},{"nctId":"NCT03730142","phase":"PHASE1","title":"A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma","status":"COMPLETED","sponsor":"Shanghai Jiatan Pharmatech Co., Ltd","startDate":"2018-10-25","conditions":"Advanced Cancer","enrollment":82},{"nctId":"NCT02019693","phase":"PHASE2","title":"A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-01-24","conditions":"Kidney Cancer","enrollment":20},{"nctId":"NCT04598815","phase":"PHASE2","title":"Sirolimus for Graves' Orbitopathy (GO)","status":"UNKNOWN","sponsor":"University of Pisa","startDate":"2023-06-01","conditions":"Graves Ophthalmopathy","enrollment":54},{"nctId":"NCT04470804","phase":"PHASE4","title":"Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA","status":"COMPLETED","sponsor":"Bing Han","startDate":"2020-07-01","conditions":"Pure Red Cell Aplasia, Acquired","enrollment":56},{"nctId":"NCT02042326","phase":"PHASE2","title":"Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2014-09-12","conditions":"Arteriovenous Malformations","enrollment":50},{"nctId":"NCT02913261","phase":"PHASE3","title":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-03-10","conditions":"Corticosteroid Refractory Acute Graft vs Host Disease","enrollment":310},{"nctId":"NCT02915783","phase":"PHASE2","title":"A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-02-20","conditions":"Non Clear Cell Renal Cell Carcinoma (nccRCC)","enrollment":41},{"nctId":"NCT03355794","phase":"PHASE1","title":"A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2017-11-14","conditions":"Diffuse Intrinsic Pontine Glioma, Malignant Glioma of Brain, High Grade Glioma","enrollment":19},{"nctId":"NCT02539459","phase":"PHASE2","title":"Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2015-09-23","conditions":"Sporadic Angiomyolipomas (AMLs)","enrollment":20},{"nctId":"NCT00805129","phase":"PHASE2","title":"Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-12-05","conditions":"Bladder Cancer, Metastatic Transitional Cell Carcinoma","enrollment":46},{"nctId":"NCT03163667","phase":"PHASE2","title":"CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"Calithera Biosciences, Inc","startDate":"2017-09-06","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":69},{"nctId":"NCT01668784","phase":"PHASE3","title":"Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-10-09","conditions":"Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma","enrollment":821},{"nctId":"NCT05490095","phase":"PHASE1","title":"Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults","status":"COMPLETED","sponsor":"Sovargen","startDate":"2021-07-23","conditions":"Pharmacokinetics","enrollment":26},{"nctId":"NCT03434704","phase":"PHASE2","title":"Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole","status":"COMPLETED","sponsor":"Ciceri Fabio","startDate":"2018-06-18","conditions":"Transplant-Related Hematologic Malignancy, Leukemia, Acute, Myelodysplastic Syndromes","enrollment":10},{"nctId":"NCT05458492","phase":"PHASE2","title":"Sirolimus in Cutaneous Sarcoidosis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-07","conditions":"Sarcoidosis, Cutaneous Sarcoidosis","enrollment":10},{"nctId":"NCT03589976","phase":"PHASE2","title":"A Futility Trial of Sirolimus in Multiple System Atrophy","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2018-09-01","conditions":"Multiple System Atrophy","enrollment":47},{"nctId":"NCT01529554","phase":"PHASE1, PHASE2","title":"Controlled Level EVERolimus in Acute Coronary Syndromes","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2015-01-08","conditions":"Acute Coronary Syndromes","enrollment":150},{"nctId":"NCT04247750","phase":"PHASE2","title":"Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP)","status":"UNKNOWN","sponsor":"Università degli Studi di Ferrara","startDate":"2021-04-13","conditions":"Beta-Thalassemia","enrollment":45},{"nctId":"NCT01263951","phase":"PHASE2","title":"Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone","status":"UNKNOWN","sponsor":"Thomas Jefferson University","startDate":"2010-11","conditions":"Differentiated Thyroid Cancer","enrollment":35},{"nctId":"NCT00936858","phase":"PHASE2","title":"RAD001 for Patients With Radioiodine Refractory Thyroid Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-07","conditions":"Thyroid Cancer","enrollment":50},{"nctId":"NCT03525834","phase":"PHASE4","title":"Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-09","conditions":"Renal Angiomyolipoma","enrollment":40},{"nctId":"NCT02596828","phase":"PHASE2","title":"Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2016-04","conditions":"Pineoblastoma","enrollment":4}],"_emaApprovals":[],"_faersSignals":[{"count":67,"reaction":"OFF LABEL USE"},{"count":15,"reaction":"DEATH"},{"count":13,"reaction":"HEADACHE"},{"count":11,"reaction":"DIARRHOEA"},{"count":10,"reaction":"LUNG TRANSPLANT"},{"count":8,"reaction":"PRODUCT DISPENSING ERROR"},{"count":8,"reaction":"STOMATITIS"},{"count":8,"reaction":"THERAPY CESSATION"},{"count":7,"reaction":"NAUSEA"},{"count":7,"reaction":"PRODUCT SUBSTITUTION ISSUE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RaparoBell® Tab."],"phase":"marketed","status":"active","brandName":"Sirolimus Tab.","genericName":"Sirolimus Tab.","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sirolimus inhibits mTOR (mammalian target of rapamycin), a key signaling protein that controls cell growth and proliferation. Used for Prophylaxis of organ rejection in patients receiving renal transplants, Lymphangioleiomyomatosis (LAM), Tuberous sclerosis complex (TSC)-associated tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}